These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38130409)

  • 1. Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against
    Jacobsson S; Golparian D; Oxelbark J; Kong FYS; Da Costa RMA; Franceschi F; Brown D; Louie A; Drusano G; Unemo M
    Front Pharmacol; 2023; 14():1291885. PubMed ID: 38130409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic Evaluation of Zoliflodacin Treatment of
    Jacobsson S; Golparian D; Oxelbark J; Franceschi F; Brown D; Louie A; Drusano G; Unemo M
    Front Pharmacol; 2022; 13():874176. PubMed ID: 35496288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against
    Jacobsson S; Golparian D; Oxelbark J; Alirol E; Franceschi F; Gustafsson TN; Brown D; Louie A; Drusano G; Unemo M
    Front Pharmacol; 2021; 12():682135. PubMed ID: 34093206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae.
    Foerster S; Drusano G; Golparian D; Neely M; Piddock LJV; Alirol E; Unemo M
    J Antimicrob Chemother; 2019 Dec; 74(12):3521-3529. PubMed ID: 31730160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating
    Jacobsson S; Golparian D; Oxelbark J; Wicha WW; da Costa RMA; Franceschi F; Brown D; Louie A; Gelone SP; Drusano G; Unemo M
    Front Pharmacol; 2022; 13():1035841. PubMed ID: 36452226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonococcal resistance to zoliflodacin could emerge via transformation from commensal Neisseria species. An in-vitro transformation study.
    Abdellati S; Laumen JGE; de Block T; De Baetselier I; Van Den Bossche D; Van Dijck C; Manoharan-Basil SS; Kenyon C
    Sci Rep; 2024 Jan; 14(1):1179. PubMed ID: 38216602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.
    Unemo M; Ahlstrand J; Sánchez-Busó L; Day M; Aanensen D; Golparian D; Jacobsson S; Cole MJ;
    J Antimicrob Chemother; 2021 Apr; 76(5):1221-1228. PubMed ID: 33564854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea.
    Unemo M; Golparian D; Oxelbark J; Kong FYS; Brown D; Louie A; Drusano G; Jacobsson S
    J Antimicrob Chemother; 2024 May; 79(5):1006-1013. PubMed ID: 38497988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GyrB in silico mining in 27 151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility.
    Golparian D; Jacobsson S; Sánchez-Busó L; Bazzo ML; Lan PT; Galarza P; Ohnishi M; Unemo M
    J Antimicrob Chemother; 2022 Dec; 78(1):150-154. PubMed ID: 36308328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility Trends of Zoliflodacin against Multidrug-Resistant
    Le W; Su X; Lou X; Li X; Gong X; Wang B; Genco CA; Mueller JP; Rice PA
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing novel partner antimicrobials to protect ceftriaxone against gonococcal resistance: An in vitro evaluation.
    Abdellati S; Gestels Z; Baranchyk Y; de Block T; Van Den Bossche D; De Baetselier I; Manoharan-Basil SS; Kenyon C
    Int J STD AIDS; 2024 Nov; 35(13):1042-1049. PubMed ID: 39226039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial Resistance in Neisseria gonorrhoeae and Treatment of Gonorrhea.
    Unemo M; Golparian D; Eyre DW
    Methods Mol Biol; 2019; 1997():37-58. PubMed ID: 31119616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014.
    Kirkcaldy RD; Harvey A; Papp JR; Del Rio C; Soge OO; Holmes KK; Hook EW; Kubin G; Riedel S; Zenilman J; Pettus K; Sanders T; Sharpe S; Torrone E
    MMWR Surveill Summ; 2016 Jul; 65(7):1-19. PubMed ID: 27414503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of
    Bradford PA; Miller AA; O'Donnell J; Mueller JP
    ACS Infect Dis; 2020 Jun; 6(6):1332-1345. PubMed ID: 32329999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea.
    Taylor SN; Marrazzo J; Batteiger BE; Hook EW; Seña AC; Long J; Wierzbicki MR; Kwak H; Johnson SM; Lawrence K; Mueller J
    N Engl J Med; 2018 Nov; 379(19):1835-1845. PubMed ID: 30403954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and treatment of gonorrhoea patients in Ternopil and Dnipropetrovsk regions of Ukraine, 2013-2018.
    Boiko I; Golparian D; Krynytska I; Bezkorovaina H; Frankenberg A; Onuchyna M; Jacobsson S; Unemo M
    APMIS; 2019 Jul; 127(7):503-509. PubMed ID: 30903707
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Li X; Le W; Lou X; Wang B; Genco CA; Rice PA; Su X
    Microbiol Spectr; 2021 Oct; 9(2):e0018121. PubMed ID: 34668731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge.
    Unemo M
    BMC Infect Dis; 2015 Aug; 15():364. PubMed ID: 26293005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibilities of strains of Neisseria gonorrhoeae in Bangkok, Thailand: 1994-1995.
    Knapp JS; Wongba C; Limpakarnjanarat K; Young NL; Parekh MC; Neal SW; Buatiang A; Chitwarakorn A; Mastro TD
    Sex Transm Dis; 1997 Mar; 24(3):142-8. PubMed ID: 9132980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Neisseria gonorrhoeae in the United States: Summary of Evidence From the Development of the 2020 Gonorrhea Treatment Recommendations and the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Treatment Guidelines.
    Barbee LA; St Cyr SB
    Clin Infect Dis; 2022 Apr; 74(Suppl_2):S95-S111. PubMed ID: 35416971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.